Abstract OT1-03-02: MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and …

R Baird, A Omlin, J Kiemle-Kallee, U Fiedler, C Zitt… - Cancer Research, 2018 - AACR
J Kiemle-Kallee; J Kiemle-Kallee … R Baird, A Omlin, J Kiemle-Kallee, U Fiedler, C Zitt, D
Feurstein, J Herbst, K Dawson, E vom Baur, M Stumpp, F Hermann, A Harstrick, A Schneeweiss; …

Alveolar macrophages in idiopathic pulmonary fibrosis display a more monocyte-like immunophenotype and an increased release of free oxygen radicals

J Kiemle-Kallee, H Kreipe, HJ Radzun… - European …, 1991 - Eur Respiratory Soc
Bronchoalveolar lavage (BAL) was performed in 13 patients with idiopathic pulmonary
fibrosis (IPF) and in 10 control subjects. Free oxygen radical (FOR) production of alveolar …

Proliferation, macrophage colony-stimulating factor, and macrophage colony-stimulating factor-receptor expression of alveolar macrophages in active sarcoidosis.

…, K Heidorn, J Barth, J Kiemle-Kallee… - … ; a Journal of …, 1990 - europepmc.org
Alveolar macrophages (AM) in sarcoidosis display an enhanced mitotic activity.
Immunocytochemical detection of the proliferation-associated Ki-67 antigen revealed significant …

Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in …

…, I Adkins, S Tillmanns, J Kiemle-Kallee… - 2022 - ascopubs.org
2502 Background: SOT101 (previously SO-C101) is a fusion protein of IL-15 and the IL-15
receptor α sushi+ domain. Synergistic effects of SOT101 and an anti-programmed cell death …

Abstract P4-21-18: Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®

…, I Dolado, J Herbst, KM Dawson, J Kiemle-Kallee - Cancer Research, 2017 - AACR
Background: HER2 positivity is an important predictive factor for treatment with anti-HER2
agents in several cancers. However, currently available monoclonal antibody and tyrosine …

Diminished activity of tartrate resistant acid phosphatase in alveolar macrophages from patients with active sarcoidosis.

J Barth, H Kreipe, J Kiemle-Kallee, HJ Radzun… - Thorax, 1988 - thorax.bmj.com
Alveolar macrophages differ from their percursors in blood, monocytes, by expressing strong
activity of the tartrate resistant variant of acid phosphatase (TAcP). A study was carried out …

716 AURELIO-04: A phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients …

…, LP Jelinkova, I Adkins, S Tillmanns, J Kiemle-Kallee… - 2022 - jitc.bmj.com
Background SOT101 (INN: nanrilkefusp alfa), a fusion protein of IL-15 and the IL-15 receptor
α sushi+ domain, was investigated in AURELIO-03 (NCT04234113), a phase 1 dose-…

Abstract CT149: MP0250, a VEGF-and HGF-blocking multi-DARPin drug candidate, in combination with tyrosine-kinase-inhibitors targeting EGFR-mutated NSCLC …

J Kiemle-Kallee, U Fiedler, KM Dawson, J Haunschild… - Cancer Research, 2018 - AACR
Background: Relapse of patients with EGFR-mutated NSCLC treated with TKI regimens is
most often due to TK mutation but also in a significant number of cases due to upregulation of …

Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy …

…, R Sachse, S Tillmanns, D Bechard, J Kiemle-Kallee… - Cancer Research, 2022 - AACR
Introduction: SOT101 (previously SO-C101), a fusion protein of IL-15 and the IL-15 receptor
α sushi+ domain, was investigated in an open-label, multicenter, dose-escalation study as …

Retinoide in der Onkologie

J Kiemle-Kallee, F Porzsolt - DMW-Deutsche Medizinische …, 1993 - thieme-connect.com
Die Behandlungserfolge: rnit dein Vit-amin-A-Derivat Tretinoin {all-trcins-Retinsäurel bei
der akuten Prurnyelozytenleukämie haben das inter-esse für den Einsatz von weiteren …